The world of cholesterol testing is undergoing a quiet revolution, one that challenges the long-held belief that measuring 'bad' cholesterol is the key to preventing heart attacks. While lowering LDL cholesterol has undoubtedly saved countless lives, a deeper dive into the science reveals a more nuanced picture of cardiovascular risk. As an expert commentator, I explore the evolving landscape of cholesterol testing, the limitations of traditional methods, and the emergence of more sophisticated approaches that could shape the future of heart health care.
The Limitations of LDL
For decades, the focus on LDL cholesterol has been a cornerstone of cardiovascular medicine. Lowering LDL cholesterol has been shown to reduce heart attacks, strokes, and early death. However, as the source material highlights, this approach doesn't tell the whole story. LDL cholesterol measures the amount of cholesterol carried by low-density lipoprotein particles, but it doesn't account for the fact that two people can have the same LDL cholesterol level yet very different numbers of particles, and therefore different levels of risk. This limitation has prompted researchers to seek more comprehensive ways of measuring risk.
The Rise of ApoB
Apolipoprotein B, or apoB, is a more recent entrant into the cholesterol testing arena. It reflects the total number of cholesterol-carrying particles in the blood, rather than just the amount of cholesterol they contain. A growing body of research suggests that apoB is a more accurate way of identifying who is at risk and who isn't. In March 2026, the American Heart Association and American College of Cardiology acknowledged apoB as a potentially more precise marker, in line with earlier European recommendations.
However, despite its superior accuracy, apoB has not yet filtered into routine care. Part of the reason is inertia. LDL cholesterol has been a scientific breakthrough and a public health success story for decades. It's simple, widely understood, and directly linked to treatments that work. As Allan Sniderman, a cardiologist at McGill University, notes, 'For 50 years, LDL cholesterol was an amazing discovery. It's not that it isn't a good marker. It is a good marker.'
The Nuance of Cholesterol Testing
The challenge is not choosing one marker over another, but understanding what each one captures, and what it misses. Kausik Ray, a cardiologist at Imperial College London, emphasizes that 'We're not interested in cholesterol for its own sake. We're trying to prevent heart attacks and strokes.' Cholesterol enters artery walls through apoB-containing particles, but those particles are not all the same. LDL makes up most of them, but lipoprotein(a) and triglyceride-rich particles also play a role. ApoB captures the total number, but not their source.
An elevated apoB could be driven by different underlying problems—high LDL, insulin resistance, obesity, or genetic factors—and each may require a different intervention. As Ray points out, 'If you only had apoB, you don't know whether to focus on LDL-lowering or weight loss or glucose control.' This is where nuance comes in. ApoB may be a better overall signal of risk, but clinicians still need to understand what is driving it.
The Future of Cholesterol Testing
The need for a more detailed picture is already pushing cholesterol testing beyond a single number. Both Ray and Børge Nordestgaard, president of the European Atherosclerosis Society, point to lipoprotein(a), a genetically determined form of cholesterol that is rarely measured but can significantly increase risk. Nordestgaard argues that if lipid testing were designed from scratch today, it would not center on a single measure at all. Instead, you would test your LDL cholesterol, your remnant cholesterol, and your lipoprotein(a).
The shift is not just about better markers, but earlier detection. Cardiovascular risk builds silently over decades, yet testing often begins only once symptoms or clear risk factors appear, such as being male and over 60. As Ray notes, 'If you don’t look, you don’t know. Typically, people in their twenties, thirties, forties are often not going to have things checked, because they feel fine.'
The Complexity of Cardiovascular Risk
Beyond apoB, researchers are beginning to explore even more granular ways of measuring risk. Large-scale examinations of the chemical molecules produced by the body's metabolism, alongside genetic data, suggest that cardiovascular risk is shaped by a complex interplay of biological pathways, not a single biomarker. One analysis found that combining metabolic and genetic information can improve risk prediction beyond traditional cholesterol measures, helping to explain why people with similar profiles can have very different outcomes.
The challenge is translating that complexity into clinical practice. More detailed testing brings higher costs, greater analytical burden, and the need for new evidence to guide treatment decisions. For researchers, the direction of travel is clear. Medicine must move away from single-number diagnostics toward more layered, data-driven assessments of risk.
The Takeaway
The future of cholesterol testing is not about a single, simple measure, but a more nuanced, multi-faceted approach. ApoB is a step in the right direction, but it's just one piece of the puzzle. As Ray says, 'This whole concept of normal—we’ve got to get rid of that and explain to people there’s a continuum for all of these things. There isn’t a black-and-white answer, unfortunately.' The journey towards a more comprehensive understanding of cardiovascular risk is just beginning, and it promises to reshape the way we think about and manage heart health.
